2026-05-17T00:20:34Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/231692024-11-28T23:26:03Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Roman-Rodriguez, Miguel author Kaplan, Alan author 2021 In its 2021 strategy report, the Global Initiative for Chronic Obstructive Lung Disease states: we no longer refer to asthma-COPD overlap (ACO), instead we emphasize that asthma and COPD are different disorders, although they may [...] coexist in an individual patient. If a concurrent diagnosis of asthma is suspected, pharmacotherapy should primarily follow asthma guidelines, but pharmacological and non-pharmacological approaches may also be needed for their COPD. What does this mean for the treating physician? In this review, we explore the implications of this new guidance on treating patients with chronic obstructive pulmonary disease, arguing for a personalized approach to treatment. Roman-Rodriguez M, Kaplan A. GOLD 2021 Strategy Report: Implications for Asthma-COPD Overlap. Int J Chronic Obstr Pulm Dis. 2021;16:1709-15. 10.2147/COPD.S300902 1178-2005 International Journal of Chronic Obstructive Pulmonary Disease https://hdl.handle.net/20.500.13003/19610 34163155 L2007625886 2-s2.0-85108723989 https://hdl.handle.net/20.500.12105/23169 662308400001 COPD Asthma Asthma-COPD overlap Inhaled corticosteroid Bronchodilator GOLD 2021 Strategy Report: Implications for Asthma-COPD Overlap